BLING III: A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients [ 2017 - 2021 ]

Research Grant

Researchers: Prof Jeffrey Lipman (Principal investigator) ,  Dr Joel Dulhunty ,  Prof David Paterson ,  Prof Jason Roberts ,  Prof John Myburgh
View all 7 related researchers

Brief description This Australian-led trial of global significance will provide definitive clinical evidence of the optimal method for treating patients with severe sepsis using beta-lactam antibiotics. The trial will compare whether continuous infusion of beta-lactam antibiotics improves outcomes for patients compared with standard intermittent dosing. The potential significance of this trial is that it may lead to a simple and cost-effective intervention to improve survival for patients with severe infections.

Funding Amount $AUD 3,354,602.11

Funding Scheme Project Grants

Notes Standard Project Grant